What it's for (Indications)
- Gentamicin, an aminoglycoside antibiotic, is indicated for the treatment of serious bacterial infections caused by susceptible strains of microorganisms.
- These primarily include severe systemic infections caused by Gram-negative bacteria, such as *Pseudomonas aeruginosa*, *Klebsiella spp.
- *, *Enterobacter spp.
- *, *Serratia spp.
- *, *Proteus spp.
- *, *Escherichia coli*, and *Citrobacter spp.
- * Specific indications encompass complicated and recurrent urinary tract infections, hospital-acquired pneumonia, sepsis, intra-abdominal infections (often in combination with other antibiotics active against anaerobes), meningitis, and osteomyelitis.
- Gentamicin is also utilized in combination with other antimicrobial agents (e.
- g.
- , penicillin or vancomycin) for the synergistic treatment of serious Gram-positive infections, such as endocarditis caused by *Streptococcus viridans* or *Enterococcus faecalis*, and for certain staphylococcal infections.
- Topical formulations are used for ocular and skin infections.
- The decision to use gentamicin should be based on culture and susceptibility results, as well as the severity of the infection, considering its potential for nephrotoxicity and ototoxicity.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Gentamicin dosage must be carefully individualized based on the patient's weight, renal function, severity of infection, and the susceptibility of the causative organism. For adults with normal renal function, the typical intravenous or intramuscular dosage for serious systemic infections ranges from 3 to 5 mg/kg/day, usually administered as 1 to 2 mg/kg every 8 hours, or as a single daily dose of 5 to 7 mg/kg for once-daily dosing regimens. This once-daily approach is often preferred due to potential for reduced nephrotoxicity and similar efficacy, though it is not suitable for all patients or infection types. Peak and trough serum concentrations must be meticulously monitored to ensure therapeutic efficacy and minimize toxicity, especially for conventional multiple daily dosing. Trough concentrations should generally be less than 1-2 mcg/mL. In patients with impaired renal function, significant dose reduction or extension of dosing intervals is essential, guided by creatinine clearance. Pediatric dosing also varies by age and weight. Topical and ophthalmic preparations have specific dosing schedules unrelated to systemic absorption concerns. Strict adherence to dosing guidelines and therapeutic drug monitoring is paramount to optimize patient outcomes and safety. |
Safety & Warnings
Common Side Effects
- Gentamicin is associated with several significant side effects, primarily nephrotoxicity and ototoxicity, which can be severe and irreversible.
- Nephrotoxicity, characterized by acute tubular necrosis, often manifests as elevated serum creatinine and blood urea nitrogen levels, decreased urine output, and electrolyte imbalances.
- This risk is dose-dependent, prolonged treatment-dependent, and increased in patients with pre-existing renal impairment, dehydration, or concurrent use of other nephrotoxic drugs.
- Ototoxicity can manifest as vestibular (e.
- g.
- , dizziness, vertigo, ataxia, nystagmus) or cochlear (e.
- g.
- , tinnitus, hearing loss) damage.
- Both forms of ototoxicity can be permanent.
- Other less common but serious side effects include neuromuscular blockade, which can lead to respiratory depression or paralysis, particularly in patients with underlying neuromuscular disorders (e.
- g.
- , myasthenia gravis) or those receiving neuromuscular blockers.
- Hypersensitivity reactions, including rash, pruritus, urticaria, and rarely anaphylaxis, can occur.
- Gastrointestinal disturbances such as nausea, vomiting, and diarrhea are also reported.
- Hematologic abnormalities, including anemia, leukopenia, and thrombocytopenia, have been observed.
- Regular monitoring of renal function, audiometric assessments, and therapeutic drug monitoring are crucial to detect and manage these adverse effects proactively.
Serious Warnings
- Black Box Warning: Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, Gentamicin Injection is potentially nephrotoxic; the risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage or prolonged therapy. Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in patients with renal impairment and in those on high doses and/or prolonged therapy.
- Gentamicin carries several significant warnings due to its potential for serious adverse effects.
- The most critical warnings relate to its potential for nephrotoxicity and ototoxicity (vestibular and cochlear), which can be permanent.
- Patients receiving gentamicin must undergo regular monitoring of renal function (serum creatinine, blood urea nitrogen, urine output) and auditory/vestibular function (audiograms, balance assessments) throughout treatment, especially in those with pre-existing renal impairment, the elderly, or those on prolonged therapy.
- Concurrent use with other nephrotoxic or ototoxic drugs, such as loop diuretics (e.
- g.
- , furosemide), cisplatin, vancomycin, or cyclosporine, significantly increases these risks and should be avoided or managed with extreme caution and intensified monitoring.
- Neuromuscular blockade and respiratory paralysis have been reported with aminoglycosides, particularly in patients with neuromuscular disorders (e.
- g.
- , myasthenia gravis) or in those receiving neuromuscular blocking agents; careful monitoring for signs of respiratory depression is essential.
- Gentamicin should be used with caution in premature infants and neonates due to renal immaturity and a prolonged serum half-life.
- Adequate hydration is crucial to minimize renal toxicity.
- The benefits of therapy must be carefully weighed against the risks of these severe toxicities, and the lowest effective dose for the shortest possible duration should always be employed.
How it Works (Mechanism of Action)
Gentamicin is an aminoglycoside antibiotic that exerts its potent bactericidal effect by interfering with bacterial protein synthesis. Its primary mechanism involves irreversible binding to the bacterial 30S ribosomal subunit. This critical interaction occurs at specific ribosomal proteins and ribosomal RNA sites, leading to a cascade of detrimental effects on the bacterial cell. Specifically, gentamicin disrupts the initiation complex formation, preventing the ribosome from correctly assembling to begin the translation process. Furthermore, it causes a dose-dependent misreading of the messenger RNA (mRNA) code, leading to the incorporation of incorrect amino acids into nascent polypeptide chains. This results in the synthesis of aberrant, non-functional, or truncated bacterial proteins. The drug also induces premature termination of protein synthesis and can cause the breakup of polysomes into non-functional monosomes. The accumulation of these faulty proteins not only impairs essential bacterial functions but also leads to increased permeability of the bacterial cell membrane, further facilitating gentamicin's entry into the cell and exacerbating its disruptive effects. Ultimately, these multifaceted disruptions to vital protein synthesis pathways lead to bacterial cell death, demonstrating its bactericidal activity against susceptible microorganisms, predominantly gram-negative aerobes.